Robert J. de Vaere
Director of Finance/CFO at VisioMedtrics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Sherman | M | 69 |
IDM Pharma, Inc.
 IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA.
Horizon Therapeutics USA, Inc.
 Horizon Therapeutics USA, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics USA, Inc. develops prescription drugs for mild to moderate pain relief arthritis. The company is headquartered in Northbrook, IL.
Horizon Pharma, Inc.
 Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 17 years |
| Todd Smith | M | 55 |
Horizon Therapeutics USA, Inc.
Horizon Therapeutics USA, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics USA, Inc. develops prescription drugs for mild to moderate pain relief arthritis. The company is headquartered in Northbrook, IL.
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 14 years |
| Michael Adatto | M | 63 |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL.
Horizon Therapeutics USA, Inc.
Horizon Therapeutics USA, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics USA, Inc. develops prescription drugs for mild to moderate pain relief arthritis. The company is headquartered in Northbrook, IL. | 14 years |
| William G. Ouchi | M | 80 |
University of California, Los Angeles
| 45 years |
| Richard W. Roll | M | 84 |
University of California, Los Angeles
| 48 years |
| Robert B. Goldberg | M | 79 |
University of California, Los Angeles
| 48 years |
| Stephan R. Targan | M | 78 |
University of California, Los Angeles
| 46 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| George Tidmarsh | M | 64 |
Horizon Therapeutics, Inc.
 Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 6 years |
| Timothy Walbert | M | 57 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA.
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 2 years |
| Michael Grey | M | 71 |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 12 years |
| Paul Hoelscher | M | 59 |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 8 years |
| Gino Santini | M | 67 |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 11 years |
| Patrick W. Dennis | M | - |
University of California, Los Angeles
| 10 years |
| Robert Metz | M | - |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 10 years |
| H. Watkins | M | 71 |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 9 years |
| Ronald E. Pauli | M | 63 |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 8 years |
| Barry L. Golombik | M | - |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
| Jeff Bird | M | 63 |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance.
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 5 years |
| Barry Moze | M | 70 | 8 years | |
| Bob Sydow | M | 69 |
University of California, Los Angeles
| 8 years |
| Marilyn Vetter | F | - | - | |
| Amy Grahn | F | - |
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | - |
| Kevin Andrew Frankel | M | - |
University of California, Los Angeles
| 7 years |
| Richard Redfern | M | 72 |
University of California, Los Angeles
| 5 years |
| Craig Anthony Zabala | M | 71 |
University of California, Los Angeles
| 5 years |
| Vikram Karnani | M | 49 | 9 years | |
| Hubert Birner | M | 57 |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 2 years |
| Robin Ann Gorelick | F | - |
University of California, Los Angeles
| 7 years |
| Kent Mouton | M | 70 |
University of California, Los Angeles
| 7 years |
| Nancy Morrison Fishbein | F | - |
University of California, Los Angeles
| 7 years |
| Pam K. Hagenah | F | - |
University of California, Los Angeles
| 7 years |
| Virinder Nohria | M | 70 | 3 years | |
| Paul R. Daza | M | 62 |
University of California, Los Angeles
| 7 years |
| Rick W. Eggert | M | - |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 1 years |
| Brian Beeler | M | 51 | 9 years | |
| Ronald Dean Ormand | M | 65 |
University of California, Los Angeles
| 6 years |
| Robert Carey | M | 65 |
Horizon Pharma, Inc.
Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL. | 5 years |
| Leon Biederman | M | - |
University of California, Los Angeles
| 4 years |
| Harold C. Hofer | M | 68 |
University of California, Los Angeles
| 7 years |
| Bonnie Feldman | M | - |
University of California, Los Angeles
| 8 years |
| John R. Watters | M | - |
University of California, Los Angeles
| 3 years |
| Larry Fink | M | 71 |
University of California, Los Angeles
| 6 years |
| John Keating | M | - |
University of California, Los Angeles
| 6 years |
| Rodrigo A. Guerra | M | 68 |
University of California, Los Angeles
| 5 years |
| Sandy Colen | M | - |
University of California, Los Angeles
| 6 years |
| Martine Rothblatt | M | 69 |
University of California, Los Angeles
| 5 years |
| Mary Martin | M | - | 1 years | |
| Emile Loria | M | 74 |
Epimmune, Inc.
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 5 years |
| Thomas St. Dennis | M | 70 |
University of California, Los Angeles
| 4 years |
| Peter J. Merlone | M | 67 |
University of California, Los Angeles
| 4 years |
| Robert Lee | M | - |
University of California, Los Angeles
| 5 years |
| Vincent M. Scardina | M | - |
University of California, Los Angeles
| 7 years |
| Chi Hiu Robert Chow | M | - |
University of California, Los Angeles
| 6 years |
| Louis C. Bock | M | 59 |
Horizon Therapeutics USA, Inc.
Horizon Therapeutics USA, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics USA, Inc. develops prescription drugs for mild to moderate pain relief arthritis. The company is headquartered in Northbrook, IL.
Horizon Therapeutics, Inc.
Horizon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Horizon Therapeutics is a late stage biopharmaceutical company focused on the development of prescription drugs for mild to moderate pain relief. It is creating novel therapies through innovative combinations of existing pharmaceutical products. The Company is building a portfolio of proprietary formulations that seek to improve safety, efficacy, and patient compliance. | 7 years |
| Bruce A. Eidelson | M | 68 |
University of California, Los Angeles
| 6 years |
| Sylvie Grégoire | M | 62 |
IDM Pharma, Inc.
IDM Pharma, Inc. Pharmaceuticals: MajorHealth Technology IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA. | 2 years |
| William Daniel | M | 72 | 9 years | |
| Tom McDowell | M | - |
University of California, Los Angeles
| 4 years |
| Donald Tringali | M | 66 |
University of California, Los Angeles
| 4 years |
| Brian Cornell | M | 65 |
University of California, Los Angeles
| 4 years |
| Munjit Johal | M | 68 |
University of California, Los Angeles
| 4 years |
| James Belardi | M | 67 |
University of California, Los Angeles
| 2 years |
| Carl Trygstad | M | - |
University of California, Los Angeles
| 11 years |
| Steven Kotlowitz | M | - |
University of California, Los Angeles
| 4 years |
| James A. Secan | M | - |
University of California, Los Angeles
| 1 years |
| Jay Whitehead | M | - |
University of California, Los Angeles
| 2 years |
| Hector Toledo | M | - |
University of California, Los Angeles
| 2 years |
| Darrell Michael Riley | M | - |
University of California, Los Angeles
| 4 years |
| Tuen-Ping Yang | M | 78 |
University of California, Los Angeles
| 1 years |
| Rosaline Chow Koo | F | - |
University of California, Los Angeles
| 5 years |
| Donna Greene | F | 61 |
University of California, Los Angeles
| 4 years |
| Kurt S. Gunderson | M | - |
University of California, Los Angeles
| 5 years |
| Mark L. Levin | M | - |
University of California, Los Angeles
| 4 years |
| Suzanne K. Wakamoto | F | - |
University of California, Los Angeles
| 5 years |
| Marcelo Sciurano | M | - |
University of California, Los Angeles
| 6 years |
| Barry Becker | M | - |
University of California, Los Angeles
| 2 years |
| Samir Sabri Samaan Shammas | M | - |
University of California, Los Angeles
| 4 years |
| Roland R. Perry | M | - |
University of California, Los Angeles
| 2 years |
| Michael J. Means | M | 62 |
University of California, Los Angeles
| 4 years |
| Alphonse H. L. Chan | M | - |
University of California, Los Angeles
| 4 years |
| Linda Havard | F | 68 |
University of California, Los Angeles
| 2 years |
| Katherine Herrick Drake | F | - |
University of California, Los Angeles
| 2 years |
| Byron Brand Snider | M | - |
University of California, Los Angeles
| 4 years |
| Marc Graboff | M | - |
University of California, Los Angeles
| 4 years |
| Marc Reich | M | - |
University of California, Los Angeles
| 4 years |
| Thomas E. Hill | M | - |
University of California, Los Angeles
| 4 years |
| Kathryn Falberg | F | 63 |
University of California, Los Angeles
| 4 years |
| Lance Gouthro | M | - |
University of California, Los Angeles
| 4 years |
| Jan Loeys | M | - |
University of California, Los Angeles
| 5 years |
| Jay F. Shepherd | M | - |
University of California, Los Angeles
| 4 years |
| Paul Richardson | M | - |
University of California, Los Angeles
| 4 years |
| Ty N. Odeh | M | - |
University of California, Los Angeles
| 4 years |
| David Chen | M | - |
University of California, Los Angeles
| 1 years |
| Josh L. Green | M | 68 |
University of California, Los Angeles
| 4 years |
| David S. Hamilton | M | - |
University of California, Los Angeles
| 4 years |
| Adele Linda Canetti | F | - |
University of California, Los Angeles
| 5 years |
| John Schauerman | M | 67 |
University of California, Los Angeles
| 4 years |
| Christopher Sohn | M | 63 |
University of California, Los Angeles
| 4 years |
| Bruce Hallett | M | - |
University of California, Los Angeles
| 3 years |
| Howard Brand | M | - |
University of California, Los Angeles
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 93 | 93.00% |
| Ireland | 16 | 16.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Robert J. de Vaere
- Personal Network
